Gilead Sciences and its subsidiary Dodgers Merger Sub plan to acquire Kite Pharma for $11.9bn.

Both the acquirer and target companies are biopharmaceutical companies based in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The acquisition will enable Gilead Sciences to expand its presence in the oncology and cell therapy areas, while also enabling Kite Pharma to progress the development of its pipeline.

"Clinical-stage biotechnology company RegenxBio plans to acquire rare disease company Dimension Therapeutics."

Clinical-stage biotechnology company RegenxBio plans to acquire rare disease company Dimension Therapeutics.

The acquisition will be made by RegenxBio’s wholly owned subsidiary Muddy Charles Acquisition Corporation (Merger Sub) and enhance Regenxbio’s gene therapy product pipeline.

All companies involved in the acquisition are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now